DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
NARATUXIMAB EMTANSINE
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Leukocyte antigen CD37 binding agent
NARATUXIMAB EMTANSINE
×
Maximum Phase:
1
First Approval:
None
UNII:
WE1X5A83B9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-220
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MDX-220
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MONO-DGA-RFB4
1
Antibody
Investigational
Unknown
Unknown
Lymphoma
CD22 binding agent
MONO-DGA-RFB4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KHK-2866
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Proheparin-binding EGF-like growth factor inhibitor
KHK-2866
×
Maximum Phase:
1
First Approval:
None
UNII:
111EN0IJ7C
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CSL-360
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha inhibitor
CSL-360
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
URABRELIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
URABRELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
W6284A5K8N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TALQUETAMAB
1
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Hematologic Neoplasms
G-protein coupled receptor family C group 5 member D binding agent
TALQUETAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4W3KFI3TN3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6895882
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RO6895882
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CUDAROLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
CUDAROLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
DT958C4NWR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAVURUTAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PAVURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7594
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-7594
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPITUMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
EPITUMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
3VD89OE565
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-033
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MDX-033
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUCOTUZUMAB CELMOLEUKIN
1
Antibody
Investigational
Unknown
Unknown
Ovarian Neoplasms
Epithelial cell adhesion molecule other
TUCOTUZUMAB CELMOLEUKIN
×
Maximum Phase:
1
First Approval:
None
UNII:
4ON7FF680U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-015
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Teratocarcinoma-derived growth factor 1 binding agent
BIIB-015
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 other
SONTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIRNOVETMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TIRNOVETMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMROTAMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Squamous Cell; Histiocytoma, Malignant Fibrous
Unknown
SAMROTAMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
SY5HF6N5MB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-639
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-639
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLYSYN
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Tyrosine-protein kinase receptor FLT3 inhibitor
FLYSYN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-1303
1
Antibody
Investigational
Unknown
Unknown
Anthrax; Hypersensitivity
Protective antigen inhibitor
MDX-1303
×
Maximum Phase:
1
First Approval:
None
UNII:
7D0R3114J3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NIDANILIMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
NIDANILIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
FORAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
377VY97V7S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DUVORTUXIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
DUVORTUXIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
J545GSE96Y
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-191
1
Antibody
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Stem cell growth factor receptor inhibitor
AMG-191
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLANVOTUMAB
1
Antibody
Investigational
Unknown
Unknown
Melanoma
5,6-dihydroxyindole-2-carboxylic acid oxidase other
FLANVOTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
ZNV4738BS6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANELIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MANELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
U3OZ7HX207
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-167
1
Antibody
Investigational
Unknown
Unknown
Bone Diseases, Metabolic
Sclerostin inhibitor
AMG-167
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KRN-330
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Cell surface A33 antigen binding agent
KRN-330
×
Maximum Phase:
1
First Approval:
None
UNII:
A64J777I28
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CYT-500 177LU
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms
Glutamate carboxypeptidase II binding agent
CYT-500 177LU
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINTUZUMAB ACTINIUM AC-225
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LINTUZUMAB ACTINIUM AC-225
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-565
1
Antibody
Investigational
Unknown
Unknown
Adenocarcinoma
Carcinoembryonic antigen-related cell adhesion molecule 5 cross-linking agent
MEDI-565
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
8
9
10
11
12
13
14
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA